SBRA Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Sabra Healthcare REIT (SBRA) is currently trading at $17.34 as of 2025-03-24. The stock is showing signs of a potential bullish trend with a MACD crossover and rising Stochastic Oscillator. The RSI is at 52.10, indicating a neutral position, not overbought or oversold.
Fibonacci Levels:
The Fibonacci levels suggest resistance at $17.77 (R1) and $18.15 (R2), with support at $16.51 (S1) and $16.13 (S2). The stock is currently approaching the first resistance level.
News and Analyst Sentiment:
Recent analyst reports indicate a mix of Buy and Hold ratings. Bank of America and JMP Securities have Buy ratings with price targets of $21 and $20, respectively. However, KeyBanc and Truist maintain a Hold rating. The average price target is $19.67, suggesting a 13% upside.
Financial Performance:
SBRA reported strong Q4 2024 results with AFFO meeting expectations. The company projects positive growth for FY25, supported by a solid balance sheet and a P/E ratio of 38.35.
Conclusion:
Based on the analysis, SBRA is expected to rise to $18.10 in the next trading week. The bullish technical indicators and positive analyst sentiment support this outlook.
Recommendation: Buy SBRA with a target price of $18.10.
SBRA Similar Chart Price Prediction
The price of SBRA is predicted to go up -7.71%, based on the high correlation periods with LPG. The similarity of these two price pattern on the periods is 93.94%.
SBRA
LPG
Down: -7.71%Similarity: 93.94%
SBRA Revenue Forecast
SBRA EPS Forecast
SBRA FAQs
What is SBRA revenue forecast for next quarter？
SBRA Analyst's Forecast
Michael Lewis
Truist Securities
Hold
2025-03-18
Price Target
$17 → $18
Upside
+1.24%
Truist raised the firm's price target on Sabra Health Care to $18 from $17 and keeps a Hold rating on the shares. The risk of recession has increased and the 10-year Treasury rate has fallen since the firm's downgrade of the stock in January, the analyst tells investors in a research note. Notwithstanding risks to Medicaid funding, select healthcare REITs might generally be relatively defensive within the sector if macroeconomic trends continue to worsen, Truist adds.
Aaron Hecht
JMP Securities
Hold → Buy
2025-01-07
Price Target
$20
Upside
+16.41%
Nicholas Yulico
Scotiabank
Hold
2024-10-11
Price Target
$17 → $18
Downside
-0.11%
